GLP-1R agonists demonstrate cardiovascular protection through anti-inflammatory, anti-atherosclerotic, and cardiac-specific mechanisms beyond glucose control, with proven benefits in T2D, obesity, CKD, and HFpEF.
Multi-trial provenGLP-1 cardiovascular protection proven across diabetes (LEADER), obesity (SELECT), kidney disease (FLOW), and heart failure (STEP-HFpEF) landmark trials
What the researchers found
GLP-1R agonists: cardiovascular protection via anti-inflammatory, anti-atherosclerotic, cardiac-specific mechanisms. Proven in T2D (LEADER, SUSTAIN-6), obesity (SELECT), CKD (FLOW), HFpEF (STEP-HFpEF). Weight-independent benefits.
Why it matters
GLP-1 drugs may be the most important cardiovascular development since statins, with benefits across multiple disease states.
How the study worked
Review of basic science mechanisms and cardiovascular outcome trial results for GLP-1R agonists.
What this study cannot tell us
Short review. Mechanism-outcome linkage not always proven. Some trials still ongoing.
How to read the evidence
Review of multiple landmark RCTs. Highest evidence level.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs are evolving from diabetes medications to comprehensive cardiometabolic therapies protecting the heart, blood vessels, and kidneys.
Questions still open
- Will GLP-1 drugs be prescribed specifically for cardiovascular protection regardless of diabetes?
- Which cardiac mechanism is most important for clinical benefit?
- Should all high-CV-risk patients receive GLP-1 drugs?
Common questions
Are GLP-1 drugs heart medicines?
Should non-diabetic heart patients take GLP-1 drugs?
Read the original research
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease.
Annual review of medicine, 77(1), 1-15
Citation
Ibe, Tatsuro; Borlaug, Barry A. (2026). Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease.. Annual review of medicine, 77(1), 1-15. https://doi.org/10.1146/annurev-med-043024-011141